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The small GTPase Rho regulates cell morphogenesis through remodeling of the actin cytoskeleton. While
Rho is overexpressed in many clinical cancers, the role of Rho signaling in oncogenesis remains unknown.
mDia1 is a Rho effector producing straight actin filaments. Here we transduced mouse embryonic fibroblasts
from mDia1-deficient mice with temperature-sensitive v-Src and examined the involvement and mechanism of
the Rho-mDia1 pathway in Src-induced oncogenesis. We showed that in v-Src-transduced mDia1-deficient
cells, formation of actin filaments is suppressed, and v-Src in the perinuclear region does not move to focal
adhesions upon a temperature shift. Consequently, membrane translocation of v-Src, v-Src-induced morpho-
logical transformation, and podosome formation are all suppressed in mDia1-deficient cells with impaired
tyrosine phosphorylation. mDia1-deficient cells show reduced transformation in vitro as examined by focus
formation and colony formation in soft agar and exhibit suppressed tumorigenesis and invasion when im-
planted in nude mice in vivo. Given overexpression of c-Src in various cancers, these findings suggest that
Rho-mDia1 signaling facilitates malignant transformation and invasion by manipulating the actin cytoskeleton
and targeting Src to the cell periphery.
The small GTPase Rho functions as a molecular switch in
cell morphogenesis through remodeling of the actin cytoskel-
eton (3, 14). Rho cycles between the inactive GDP-bound form
and the active GTP-bound form. This process is controlled by
guanine nucleotide exchange factors (GEFs) and GTPase-ac-
tivating proteins (GAPs) specific to Rho; the former group
catalyzes the exchange of GDP to GTP (50), and the latter
accelerates the hydrolysis of bound GTP (24). When Rho is
activated in fibroblasts, actin stress fibers are formed. Rho
proteins are frequently overexpressed in human cancers, such
as cancers of the colon and breast and lung and testicular germ
cell tumors (34). A positive correlation between the expression
level of RhoA and disease progression was also reported in
breast cancer and testicular germ cell tumors. RhoC, on the
other hand, has been repeatedly identified as a gene positively
associated with metastasis (4, 21, 40). The clinical significance
of Rho in cancer is further implicated by a discovery that a
RhoA GAP named Dlc-1 (deleted liver cancer 1) functions as
a tumor suppressor in humans (47). Thus, it was known for
some time that heterozygous deletions on chromosome 8p22
are common in human tumors, such as cancers of the breast,
prostate, lung (5, 22), and especially liver (15). Recent studies
have revealed a strong association of deletion of DLC-1 in this
region with clinical cancers, and complementary in vitro exper-
iments showed that DLC-1 functions as a potent tumor sup-
pressor, depletion of which causes RhoA hyperactivation and
results in tumorigenesis in harmony with other oncogenes,
such as Myc and Ras (47). Importantly, heterozygous deletions
in chromosome 8p22 are found to be nearly as common as that
of TP53 in clinical cancers, indicating the significant impor-
tance of DLC-1 and Rho signaling in clinical tumors (18).
Consistent with these findings, there are several reports on the
requirement of Rho activity in cell transformation in vitro. For
example, coexpression of Raf and dominant active RhoA fa-
cilitates focus formation, and expression of dominant-negative
RhoA suppresses oncogenic Ras-induced focus formation in
NIH 3T3 cells (30). In addition, active forms of Rho GEFs,
such as Dbl and Ect2, have potent transforming activities in
cultured cells in vitro (31). Thus, there are ample in vitro and
clinical data indicating the involvement of Rho signaling in
oncogenesis.
Cell transformation often leads to a change in cell morphol-
ogy. This morphological change associates with a change in the
organization of actin filaments. Nontransformed cells often
have thick bundled actin fibers known as stress fibers. When
transformed by some oncogenes, such as Ras and v-Src, the
actin stress fibers disappear and the cells dramatically alter
their shape to the round refractile cell body (49). Alternatively,
actin dot structures called podosomes are often formed. This
remodeling of the cytoskeleton is believed to contribute to
several aspects of the transformed phenotype, including adhe-
sion-independent cell growth and increased migration abilities.
Such actin remodeling associated with oncogenesis appears at
odds with the requirement of Rho signaling in oncogenesis,
because Rho activation leads to formation of actin fibers. Thus,
there is a paradox of why transformed cells require Rho sig-
naling yet show dissolution of actin cytoskeleton (27).
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Among many Rho effectors, two effector molecules, named
mDia (44) and ROCK (11), have important roles in actin
cytoskeleton remodeling (27). mDia produces straight actin
filaments by catalyzing actin nucleation and polymerization,
and ROCK activates myosin to cross-link actin filaments for
induction of actomyosin bundles and contractility. Further,
mDia is potentially linked to Rac activation and membrane
ruffle formation through c-Src-induced phosphorylation of fo-
cal adhesion proteins, and ROCK antagonizes this mDia ac-
tion (42). Thus, actin remodeling inside the cell can be deter-
mined primarily by the balance between mDia and ROCK
activities. Of the two, the involvement of ROCK in tumors has
been widely examined by the use of its small molecule inhibi-
tors, such as Y-27632 (26, 43), and the Rho-ROCK pathway
has been strongly implicated in cancer migration and tumor
metastasis and invasion. On the other hand, the role of ROCK
in oncogenesis remains ambiguous. While its requirement in
Ras-induced cell transformation was indicated by the use of
Y-27632, examination in Ras-transformed cells revealed that
the majority of ROCK is sequestered in an inactive pool by
sustained extracellular signal regulated-kinase (ERK)-mito-
gen-activated protein (MAP) kinase activity under active Ras
(33), which might be one of the mechanisms for dissolution of
stress fibers found in Ras transformants. Thus, how Rho sig-
naling contributes to oncogenesis remains an open question.
Study of Rho effectors other than ROCK has been ham-
pered by the absence of available inhibitors. Recently we gen-
erated mDia1 knockout mice (36). Here, we used mouse em-
bryonic fibroblast (MEF) cells derived from these mice and
analyzed the involvement of mDia1 and its mechanism of ac-
tion in v-Src-induced cell transformation and tumorigenesis.
v-Src is the oldest widely studied oncogene, yet it remains
unknown where in the cell it exerts its oncogenic potential. It
was previously reported that temperature-sensitive (ts) v-Src
accumulates in the perinuclear region at the restrictive tem-
perature and migrates to the periphery upon a temperature
shift in a manner dependent on the actin cytoskeleton and Rho
(6, 37). However, the underlying mechanism of this v-Src tar-
geting has not been fully elucidated, and whether this targeting
is required for v-Src-induced oncogenesis remains to be shown.
Using mDia1-deficient MEF cells, we have addressed these
questions. Here we have shown that actin filaments produced
by mDia1 are a prerequisite for v-Src targeting, and this v-Src
targeting is critical for its role in cell transformation and tu-
morigenesis. Our results further show that the Rho-mDia1
pathway functions as a link between oncogenesis and invasion.
MATERIALS AND METHODS
Plasmids, antibodies, and reagents. pEGFP-Src WT, pFL-mDia1-N3,
pEGFP-mDia1N3, and pCX vectors (pCX4bsr SV40 and pCX4puro NY72)
were described previously (1, 12, 37, 45). Primary antibodies used were mono-
clonal antibodies to mDia1 (clone 51; BD Transduction Laboratories), Src
(EC10; Upstate), cortactin (4F11; Upstate), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (6C5; Ambion), and paxillin (Z035; Invitrogen); and rabbit
polyclonal antibodies to pY416 Src (Cell Signaling Technology) and phosphoty-
rosine (Invitrogen); and rat monoclonal antibody to tubulin (YL1/2; Chemicon).
Alexa Fluor 488-, 594-, and 633-conjugated goat antibodies against rabbit, rat,
and mouse IgG(HL), Oregon green-phalloidin, Alexa Fluor 633-phalloidin,
and Texas Red X-phalloidin were purchased from Invitrogen. Horseradish per-
oxidase-conjugated sheep anti-mouse IgG, donkey anti-rabbit IgG, and goat
anti-rat IgG antibodies were purchased from GE Healthcare.
Generation of MEF cells. Mice lacking mDia1 were generated as described
previously (36). All experiments involving animals were approved by the Animal
Research Committee of Kyoto University Faculty of Medicine and carried out
following guidelines in accordance with regulations and laws set by the Japanese
government. Littermates of wild-type (WT) and mDia1/ (KO) mouse embry-
onic fibroblasts (MEFs) were obtained from embryonic day 15.5 (E15.5) embryos
from an mDia1 heterozygous mating. Cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). For retrovirus production, Plat-E cells (25), provided by T. Kitamura
(Department of Hematopoietic Factors, Institute of Medical Science, University
of Tokyo) were transfected with either pCX4bsr SV40 or pCX4puro NY72. After
48 h, the supernatant containing retrovirus was collected. To generate stable
polyclonal cell populations (WT-SV40 and KO-SV40), MEFs (1  105 cells)
were plated in 60-mm dishes. On the day of infection, the supernatant containing
retrovirus encoding simian virus 40 (SV40) T antigens and a blasticidin S-
resistant gene were added to 2 ml of growth medium in each well. After 24 h, the
virus-containing medium was aspirated and replaced with fresh growth medium.
MEF cells infected with viruses were expanded in medium for 2 days after
infection and selected with blasticidin S at a concentration of 10 g/ml for a
week. To generate stable polyclonal cell lines (WT-NY72 and KO-NY72), WT-
SV40 and KO-SV40 cells were infected with retrovirus encoding ts-v-Src (NY72)
and a puromycin-resistant gene. The cells were selected with 2 mg/ml of puro-
mycin for a week.
Activation of ts-v-src by temperature shift. ts-v-Src-expressing cells were grown
at 40°C (nonpermissive temperature) for 72 h prior to a temperature shift to
37°C (permissive temperature). For immunofluorescence, the cells were grown
on fibronectin-coated coverslips (BD Biosciences) and then fixed at various time
points with 3.7% formaldehyde in phosphate-buffered saline (PBS) prior to
staining. For immunoblotting, the cells were grown on dishes and then lysed with
Laemmli buffer at the appropriate time points.
Immunofluorescence. All procedures were carried out at room temperature.
Cells were fixed with 3.7% formaldehyde in PBS for 15 min and then perme-
abilized with 0.1% Triton X-100 in PBS for 5 min. The cells were then incubated
with PBS containing 5% bovine serum albumin (BSA) for 1 h. Primary antibod-
ies were diluted in PBS containing 5% BSA and included antibodies against Src
(1:100), mDia1 (1:100), cortactin (1:200), and pY416-Src (1:100). The secondary
antibodies used were Alexa Fluor 488- and/or 633- conjugated goat antibodies
against rabbit and/or mouse IgG(HL) (Invitrogen) diluted in PBS containing
5% BSA (1:200). F-actin was stained with Oregon-green phalloidin or Texas
Red-X phalloidin (1:200). Immunofluorescent images were acquired using a
Zeiss LSM510META confocal microscope with a 63 PlanAPO (1.4) oil im-
mersion objective and a Leica SP5 confocal imaging system (Plan-Apo, 63/1.40
numerical aperture).
Fractionation. For preparation of the P100 membrane fraction, the cells were
lysed in a hypotonic buffer containing 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 5
mM -mercaptoethanol, a phosphatase inhibitor cocktail (Roche), and a pro-
tease inhibitor mixture (Nacalai). For each sample, the lysate was centrifuged at
10,000  g for 10 min at 4°C, and the supernatant was collected and centrifuged
at 100,000  g for 60 min at 4°C. The cell pellet (P100 fraction) was collected,
dissolved in Laemmli buffer, and then analyzed by immunoblotting.
Proliferation assay. Cells (1  104 cells per dish) were seeded onto 35-mm
dishes and allowed to grow in DMEM supplemented with 10% FBS. The cells
were trypsinized and counted daily by a hemocytometer.
Video microscopy. Cell imaging using XTC cells was performed as described
previously (10, 46). XTC cells were transfected with constitutively active pFL-
mDia1-N3 and pEGFP-Src WT, with either mCherry-lifeact or mPlum-paxillin.
At 2 days after the transfection, cells were allowed to spread on a poly-L-lysine
(PLL)-coated glass coverslip in 70% Leibovitz’s L15 medium (Invitrogen) with-
out serum. After spreading, the medium was changed to 70% Leibovitz’s L15
medium supplemented with 10% FBS for 24 h. Cells were placed on the stage of
a microscope (BX52 or IX71; Olympus) equipped with either 100-W mercury or
75-W Xenon illumination and with a cooled charge-coupled-device (CCD) cam-
era (MMX1300-YHS, CoolSNAP HQ, or Cascade II:512 [Roper Scientific] or
UIC-QE [Molecular Devices]). Time-lapse imaging was performed at 21 to 23°C
using the MetaMorph software program (Universal Imaging Corp.). Fluorescent
speckle microscopy was performed by observing cells expressing a small amount
of enhanced green fluorescent protein (EGFP)-tagged proteins using a PlanApo
100 numerical-aperture 1.40 oil objective (Olympus). A restricted area near the
cell edge was illuminated.
Soft agar colony formation assay. Single-cell suspensions of 3  105 cells were
plated per 60-mm dish in 3 ml of DMEM supplemented with 10% FBS and
0.36% agar on a layer of 5 ml of the same medium containing 0.7% agar. The
plates were fed twice a week with 0.5 ml of DMEM supplemented with 10% FBS.
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Two weeks after plating, colonies were stained with 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H tetrazolium bromide (MTT) (Kishida Chemicals), and the num-
ber of colonies was determined using the Image J software program (National
Institutes of Health).
Focus formation assay. Cells were plated on 60-mm dishes in a subconfluent
fashion and cultured in DMEM supplemented with 5% FBS for a week. The
appearance of colonies of proliferating cells was visualized by Giemsa staining,
and visible colonies were counted.
In situ zymography. Glass coverslips were coated with Oregon green 488-
conjugated gelatin (0.2 mg/ml in PBS), cross-linked for 15 min in 0.5% glutar-
aldehyde in PBS, and incubated for 3 min with 5 mg/ml NaBH4 in PBS. After
incubation in DMEM at 37°C, 7.5  104 cells maintained at 40°C were plated on
coated coverslips in DMEM containing 10% FBS and then incubated at 37°C for
3 h before being processed for cell staining. Results were quantified by counting
cells degrading matrix, as defined by the ability to form at least one degradation
patch regardless of its size, and were represented as a percentage of the total (50
cells per treatment in at least three independent experiments) (2).
Matrigel invasion assay. Transwell invasion chambers (BD BioCoat Matrigel
Invasion Chamber) were used. Cells (1.5  104 cells per well) suspended in
DMEM were added to the upper compartment, and DMEM supplemented with
or without 10% FBS was applied to the lower compartment. The number of cells
that migrated across the membrane was determined 24 h later.
In vivo tumorigenicity assay. Cells (3  105 per site) in DMEM were injected
subcutaneously into the bilateral flank of 6- to 8-week-old female nude athymic
mice (BALB/c Slc-nu/nu). Widths and lengths of tumors were measured twice a
week. The tumor volume (mm3) was calculated by using the following formula:
(length  width2)/2. The mice were sacrificed at day 22, and subcutaneous
tumors were removed and fixed with 4% paraformaldehyde in 0.1 M sodium
phosphate buffer (pH 7.4) for 2 to 3 days. These tumors were then embedded in
paraffin, sectioned, and stained with hematoxylin and eosin.
Statistical analysis. Data are presented as means  standard errors (SEM).
The comparison of two groups was analyzed using Student’s unpaired two-tailed
t test or Bonferroni’s multiple-comparison test (see Fig. 2B). A P value of 0.05
was considered statistically significant.
RESULTS
v-Src-induced morphological transformation is impaired in
mDia1-deficient MEFs. We recently generated mice deficient
in mDia1 (36). Here we prepared mouse embryonic fibroblasts
(MEF cells) from wild-type (WT) and mDia1-deficient litter-
mates produced by heterozygous matings and investigated the
role of mDia1 in malignant cell transformation and tumorigen-
esis. WT and mDia1/ (KO) MEFs were first immortalized
with retroviral transfer of SV40 T antigen and the blasticidin
S-resistant gene and drug selected to produce WT-SV40 and
KO-SV40 cells. The two cell populations were then transduced
with retrovirus encoding ts-v-Src, NY72, and the puromycin
resistance gene. The tyrosine kinase of ts-v-Src is enzymatically
active at 37°C (the permissive temperature) and inactive at
40°C (the restrictive temperature) (23). By puromycin selec-
tion, we obtained WT-NY72 and KO-NY72 cell populations
(Fig. 1A). WT-NY72 and KO-NY72 cells exhibited similar
levels of expression of v-Src, and the activity of ts-v-Src at the
permissive temperature was similar in that for WT-NY72 and
KO-NY72 cell populations as examined by staining for pY416-
Src (Fig. 1B). No statistically significant difference was ob-
served in the growth of WT-NY72 and KO-NY72 cells and that
of WT-SV40 and KO-SV40 cells at either 37°C or 40°C, al-
though the growth of WT-NY72 cells always tended to be
higher than that of KO-NY72 cells (Fig. 1C). Notably, when
shifted to the permissive temperature for 24 h, WT-NY72 cells
exhibited a morphological transformation typical of the Src-
induced transformation, with a round, refractile cell body and
elongated processes, whereas KO-NY72 cells were resistant to
such morphological change and retained their extended shape
even at the permissive temperature (Fig. 1D). Both WT-NY72
and KO-NY72 cells exhibited an array of actin bundles at 40°C,
although KO-NY72 cells showed few transcytoplasmic actin
bundles compared to WT-NY72 cells. This reduction in the
actin bundles was also observed in KO-SV40 cells compared to
results for WT-SV40 cells (data not shown). However, when
maintained at 37°C, WT-NY72 cells lost actin bundles and
instead formed dot-like actin accumulation, whereas actin bun-
dles were retained in KO-NY72 cells (Fig. 1E).
Src translocation is impaired in mDia1-deficient MEFs. The
above results showed that the loss of mDia1 impaired Src-
induced morphological transformation and cytoskeletal reor-
ganization despite activation of its enzymatic activity at the
permissive temperature. To explore the mechanism of this
defect, we compared the localization of v-Src and the actin
cytoskeleton in WT-NY72 and KO-NY72 cells at various time
points following activation of ts-v-Src. ts-v-Src was reported to
accumulate in vesicles in the perinuclear region at the restric-
tive temperature and move to the periphery upon the shift to
the permissive temperature (6). During translocation, v-Src
associates with actin stress fibers and gradually accumulates in
focal adhesions. As reported, we observed the accumulation of
v-Src in the perinuclear region at the restrictive temperature in
both WT-NY72 and KO-NY72 cells (Fig. 2A). When shifted to
37°C, v-Src-containing vesicular structures began to disperse to
the cytoplasm in WT-NY72 cells, and the v-Src signals accu-
mulated in focal adhesions 4 h later (Fig. 2A; see also the
figure in the supplemental material). At 24 h after the temper-
ature shift, the v-Src signals distributed diffusely over the cell
body. On the contrary, v-Src in KO-NY72 cells continued to
stay in vesicles in the perinuclear region despite its activation
even 24 h after the temperature shift. Coincidentally, upon
v-Src activation, actin stress fibers were induced and v-Src
vesicles were found associated with these stress fibers in WT-
NY72 cells, whereas the induction of actin fibers was sup-
pressed in KO-NY72 cells. At 24 h, WT-NY72 cells began to
take a round shape with encircled actin bundles, while KO-
NY72 cells remained extended. Given mDia1 as an actin-nu-
cleating factor, these results indicated that v-Src activation
somehow promotes mDia activation and mDia1-induced actin
fibers facilitate v-Src translocation. Consistently, the actin con-
tent in the cell as measured by the fluorescence intensity of
Texas Red phalloidin staining increased time dependently to
4 h and then decreased in WT-NY72 cells, whereas it remained
almost at the same level during this period in KO-NY72 cells
(Fig. 2B). The actin content decreased further as the Src-
induced transformation progressed, as shown in Fig. 1E. We
wondered whether this mDia1-mediated v-Src translocation is
related to its membrane targeting. To this end, we prepared
the 100,000  g membrane fraction (P100) of WT-NY72 and
KO-NY72 cells at various times after the temperature shift.
The v-Src protein already was accumulating in the P100 frac-
tion 1 h after temperature shift in WT-NY72 cells, whereas this
accumulation was not found in the P100 fraction of KO-NY72
cells even at 24 h (Fig. 2C).
To gain further insight into how mDia1 works in v-Src tar-
geting to focal adhesions, we transfected Xenopus XTC fibro-
blasts with constitutively active mDia1 that lacks its N-terminal
autoinhibitory domain (N3) and Src-GFP, with either
mCherry-lifeact or mPlum-paxillin. Forty-eight hours after
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FIG. 1. mDia1 deficiency impairs v-Src-induced morphological transformation. (A) Generation of WT-NY72 and KO-NY72 cell populations.
MEFs from WT and mDia1/ (KO) littermates were immortalized with SV40 T antigen and then infected with retrovirus harboring ts-v-Src,
NY72. Populations of cells stably expressing SV40 T antigen and NY72 were isolated by two-step drug selection. (B) Expression and activation
of v-Src in WT-SV40, KO-SV40, WT-NY72, and KO-NY72 cells. The cells were maintained at 37°C. Cell lysates were prepared and probed for
	-tubulin, mDia1, Src, and pY416-Src. Ratios of the densities of pSrc to Src bands are shown below the image. (C) Proliferation of WT-SV40,
KO-SV40, WT-NY72, and KO-NY72 cells. Cells were seeded and cultured at 37°C in a 35-mm dish in DMEM containing 10% FBS and harvested
at indicated times for cell counting. Means  SEM of data from three independent experiments is shown. (D) v-Src-induced morphological
changes in WT-NY72 and KO-NY72 cells. WT-NY72 and KO-NY72 cells were grown at either 40°C or 37°C and observed under phase-contrast
microscopy. (E) Actin cytoskeleton in WT-NY72 and KO-NY72 cells. WT-NY72 and KO-NY72 cells were grown at either 40°C or 37°C, fixed, and
stained with Oregon green-phalloidin. Bars in panels D and E, 50 m.
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FIG. 2. mDia1 deficiency impairs formation of actin fibers and peripheral targeting of v-Src upon temperature shift. (A) Time course of
formation of actin fibers and v-Src translocation after temperature shift. WT-NY72 and KO-NY72 cells grown at the nonpermissive temperature
were shifted to the permissive temperature and maintained for 0, 1, 4, and 24 h. The cells were fixed and stained with an antibody against Src and
Texas Red X-phalloidin. A merged image of the two populations of cells 4 h after the temperature shift is shown in the figure in the supplemental
material. Bar, 50 m. (B) Quantification of F-actin intensity. WT-NY72 and KO-NY72 cells were cultured for 0, 1, 4, and 24 h after the
temperature shift and stained for F-actin with Texas Red X-phalloidin. The fluorescence density, i.e., the intensity divided by cell area, of each cell
was quantified and is shown (n 
 20 each). (C) Accumulation of v-Src in the P100 fraction. WT-NY72 and KO-NY72 cells were shifted to the
permissive temperature and harvested at indicated times. The P100 fraction was prepared from each population and subjected to Western blotting
for Src. v-Src signal was detected 5 kDa below the molecular mass of c-Src. The c-Src signals were not visible under the present blotting conditions.
The density of each band is shown below the blot.
4608 TANJI ET AL. MOL. CELL. BIOL.
transfection, live-cell imaging was carried out. Untransfected
XTC fibroblasts were devoid of actin stress fibers, and there
was no directed movement observed for Src-GFP. Introduction
of mDia1-N3 caused numerous actin bundles which run in
parallel, as previously reported (12). Src-GFP was seen as a
vesicular or tubular structure and was found to move along
these parallel actin fibers (Fig. 3A; see also Movie S1 in the
supplemental material). They sometimes moved from one site
to another site by extending the tubular structure to another
vesicle at a distant site and fusing with it (Fig. 3B; see also
Movie S2). Speckle microscopy of GFP-mDia1N3 revealed
that they exhibit fast processive movement, as we reported
previously (10). On the other hand, speckle microscopy of
Src-GFP revealed no such processive movement within the
time frame similar to that for GFP-mDia1N3 (data not
shown), suggesting that mDia1N3 and Src do not move as
a complex. Immunofluorescence of paxillin and live cell
imaging with mPlum-paxillin showed that Src-GFP does not
localize in large matured focal adhesions often seen near the
cell periphery, but Src-GFP sometimes colocalizes with
small paxillin signals neighboring the above matured adhe-
sions (Fig. 3C).
FIG. 3. Time-lapse video microscopy of Src-GFP in XTC cells transfected with mDia1N3. (A) Coimaging of mCherry-lifeact and Src-GFP.
XTC cells expressing mDia1N3 were identified as cells showing parallel actin fibers, and Src-GFP and mCherry-lifeact signals were monitored.
A still image is shown. Bar, 5 m. (B) Tube extension and fusion of Src-GFP signals. Src signals boxed in panel A were video monitored at 400
ms per frame at the interval of 5 s. Arrows show Src-GFP moving along actin stress fibers. Arrowheads show Src in vesicular structures.
(C) Colocalization of Src-GFP and signals for paxillin. XTC cells expressing Src-GFP and mDia1N3 were fixed and stained for paxillin (red).
Arrowheads indicate matured focal adhesions, and arrows indicate colocalization of paxillin and Src. Bar, 20 m.
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Impaired v-Src-mediated tyrosine phosphorylation in KO-
NY72 cells. The above results demonstrate that v-Src is not
properly translocated in KO-NY72 cells. To examine the con-
sequences of this impairment of v-Src in translocation, we
analyzed tyrosine phosphorylation at different time points after
the temperature shift (Fig. 4). Both WT-NY72 cells and KO-
NY72 cells exhibited elevated tyrosine phosphorylation of var-
ious proteins, as demonstrated by immunoblotting of total cell
lysates with an antiphosphotyrosine antibody (Fig. 4). Al-
though mDia1 deficiency did not alter the overall pattern of
tyrosine-phosphorylated proteins in v-Src-transformed cells,
comparison of the signal intensity in WT-NY72 cells and KO-
NY72 cells showed a visible decrease in the phosphotyrosine
signal of several proteins, especially those in the relatively high
molecular mass range (100 to 250 kDa), in KO-NY72 cells.
These results suggest that impairment of v-Src translocation
leads to downregulation of downstream signaling pathways.
Impaired transformation and invasion in vitro of KO-NY72
cells. The above findings demonstrate that in the absence of
mDia1, v-Src does not translocate to the periphery and cannot
mediate some of its signaling. We therefore next tested
whether these failures result in a defect in cell transformation.
We first subjected the two populations to colony formation in
soft agar (Fig. 5A). WT-NY72 cells formed a number of visible
colonies in 2 weeks. On the other hand, colonies KO-NY72
cells formed were significantly less in number and much
smaller in size than those of WT-NY72 cells. No colony for-
mation was found with either WT-SV40 cells or KO-SV40
cells. We then examined focus formation of the two popula-
tions. Both WT-NY72 cells and KO-NY72 cells did not show
focus formation at the restrictive temperature. While both
showed focus formation at 37°C, the number of foci in KO-
NY72 cells was significantly smaller than that in WT-NY72
cells (Fig. 5B).
Expression of Src is also associated with an increase in the
ability to invade through the extracellular matrix (ECM) (47).
Podosomes are v-Src-induced actin-rich structures on the ven-
tral surface, where proteolysis of matrix proteins occurs (20).
FIG. 4. Impaired v-Src-mediated tyrosine phosphorylation in KO-
NY72 cells. WT-NY72 and KO-NY72 cells were shifted to the per-
missive temperature and collected at the indicated times. Cell lysates
were prepared and subjected to immunoblotting with an antiphospho-
tyrosine antibody. The intensity of the phosphotyrosine signal in the
lysates of WT-NY72 and KO-NY72 cells at 4 h after the temperature
shift was determined by densitometry and is shown below.
FIG. 5. Impaired transformation in vitro of KO-NY72 cells.
(A) Soft agar colony formation. WT-SV40, KO-SV40, WT-NY72, and
KO-NY72 cells were cultured in 0.36% agarose for 2 weeks until
colonies of WT-NY72 cells became visible. Colonies were stained with
MTT, and the number of colonies in each dish was determined. The
experiment was performed in triplicate independently three times.
Shown are representative photomicrographs of WT-NY72 and KO-
NY72 cells at the time of quantification. Results are means  SEM of
data from three experiments. (B) Focus formation. WT-NY72 and
KO-NY72 cells were plated at subconfluence in 60-mm dishes and
cultured for 1 week at 37°C and 40°C. Foci were stained with Giemsa
solution, and the number was determined. Means  SEM of three
independent experiments are shown.
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We noted that dot-like actin-rich structures were formed in
WT-NY72 cells, but few were formed in KO-NY72 cells main-
tained at the permissive temperature (Fig. 1E). These struc-
tures were costained with an antibody against cortactin, a
marker of podosome, and an antibody against pSrc that is
known to localize in podosomes (Fig. 6A). These results veri-
fied that the actin-dot structures formed in WT-NY72 cells
were indeed podosomes and the podosome formation was
impaired in KO-NY72 cells. We examined a process in which
podosomes are formed in WT-NY72 cells by monitoring
mDia1 localization. At the restrictive temperature, most
mDia1 localized in the cytoplasm, but a part was found in the
extended edge of the cells, as previously reported (44), where
it overlapped with a part of the active Src signal (data not
shown). With a shift to the permissive temperature for 24 h,
mDia1 accumulates in podosomes, where it colocalizes with
active Src (Fig. 6A), suggesting that mDia1-mediated Src re-
cruitment is important for podosome formation. To examine if
these are functional podosomes, we placed WT-NY72 cells and
KO-NY72 cells on Oregon green gelatin at 37°C for 3 h. This
in situ zymography revealed extensive degradation of gelatin by
WT-NY72 cells but not by KO-NY72 cells; the percentage of
cells degrading the gelatin matrix was significantly higher in the
WT-NY72 cell population than in the KO-NY72 cell popula-
tion (Fig. 6B). Then, to examine whether the mDia1 deficiency
affects cell invasion into ECM, we performed the Matrigel
invasion assay. Cells were applied on the upper well, with or
without serum in the lower well. WT-NY72 cells exhibited
some extent of invasion without serum, but their invasion was
significantly enhanced by the addition of serum. On the other
hand, KO-NY72 cells showed little invasion without serum and
significantly less invasion than WT-NY72 cells in the presence
of serum (Fig. 6C). Independent culture confirmed that cell
viability was not affected in either population by culturing on
the Matrigel (data no shown).
mDia1-deficient cells are impaired in tumorigenesis and
invasion in vivo. We next addressed the question of whether
mDia1 deficiency affects tumor formation in vivo. WT-NY72
cells and KO-NY72 cells were implanted subcutaneously into
nude mice, and their growth was monitored. While palpable
tumors developed in all sites injected with WT-NY72 cells (6
out of 6) within 2 weeks, KO-NY72 cells exhibited a reduced
incidence of palpable tumor formation (2 out of 6) (Fig. 7A).
Determination of tumor size showed that tumors from WT-
NY72 cells developed to about 700 mm3 in volume on average
on day 18, while the size of tumors from KO-NY72 cells re-
mained less than 10 mm3 on average (Fig. 7B). Three weeks
after the cell injection, tumors were excised and their his-
tology was analyzed (Fig. 7C). A tumor formed from WT-
NY72 cells expanded to both sides of the muscle layer,
suggesting that it invaded massively. On the other hand,
KO-NY72 cells yielded only one tumor of significant size,
which was small compared to tumors from the WT cells and
showed no evidence of invasion.
DISCUSSION
In the present study, we have revealed that the Rho-mDia1
signaling facilitates translocation of v-Src to the periphery by
way of producing specific actin cytoskeleton and that this trans-
location is essential in v-Src-induced oncogenesis. Our findings
have addressed several long-standing questions on the onco-
genic mechanism of Src, namely, the identity of a molecule
responsible for Src translocation, the cellular location of Src
mediating oncogenesis, a link between oncogenesis and inva-
sion, and the clinical significance of Src activation. Our findings
have also addressed questions on Rho and the actin cytoskel-
eton in oncogenesis, that is, the effector mechanism and the
paradox of Rho signaling in oncogenesis.
mDia1-mediated Src translocation. Here we have found
that KO-NY72 cells are defective in actin stress fiber formation
upon temperature shift and are impaired in v-Src translocation
from the perinuclear region to the cell periphery. Previously it
was reported that Src translocation to the periphery requires
an intact actin cytoskeleton and Rho signaling (6, 38). How-
ever, the identity of an effector mediating Src translocation and
its mechanism of action have been elusive. Our findings dem-
onstrate that mDia1 is such an effector and mediates Src trans-
location by producing actin bundles upon temperature shift. So
how does Src move to the periphery? The SH3 domain of c-Src
is reported to be essential for this translocation, while the
myristylation and kinase activity are dispensable (7, 8). This
finding together with the finding of Tominaga et al. (41) that
Src and mDia1 bind directly by their SH3 and FH1 domains,
respectively, suggest a possibility that mDia1 and Src move
together by processive actin polymerization by mDia1. Here
we have tested this hypothesis by speckle imaging of GFP-
mDia1N3 in the presence of c-Src and of Src-GFP in the
presence of mDia1N3 in XTC cells. We have found that
while GFP-mDia1N3 exhibited fast processive movement as
reported previously (10), signals of Src-GFP did not show such
processive movement but associated with vesicular structures
that move slower than mDia1 with frequent budding and fu-
sion along actin filaments and overlap with some signals of
paxillin. While further work is required to determine the pre-
cise interaction of F-actin fibers and Src vesicles, our results
thus have identified mDia1 as a key molecule that is essential
for Src vesicle targeting to the periphery. Recently Shi et al.
used neutrophils from mDia1/ mice and showed that mDia1
is also required for translocation of hematopoietic cell kinase
(HCK), a Src family kinase in hematopoietic cells, to the lead-
ing-edge membrane and subsequent tyrosine phosphorylation
of WASP (39). Thus, the regulation by mDia1 appears to be a
general mechanism for membrane translocation of the Src
family of kinases.
Paradox of Rho signaling and the actin cytoskeleton in on-
cogenesis. There has been an issue for some time that can be
called the Rho paradox in cell transformation, that is, while
Rho is required for oncogenesis by v-Src and oncogenic Ras,
the actin filaments that are induced by Rho activation usually
disappear in transformed cells (27, 30). Sahai et al. reported
that while pharmacological intervention suggested implication
of ROCK in Ras-mediated transformation (32), the majority of
ROCK is sequestered in an inactive pool, and they suggested
that this sequestration might be one of the mechanisms for
dissolution of stress fibers found in Ras transformants (33).
However, the paradox of how the requirement for transforma-
tion and the downregulation of stress fibers could occur in the
same context remains to be solved. Here we have revealed that
mDia1 is required for actin filament formation, which is used
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FIG. 6. Impaired invasion in vitro of KO-NY72 cells. (A) Colocalization of mDia1 and pSrc in podosomes. WT-NY72 cells were shifted to the
permissive temperature for 24 h, fixed, and stained either for pSrc, F-actin, and mDia1 or for cortactin and F-actin. Bar, 50 m on the left and
20 m on the right. (B) In situ zymography of WT-NY72 and KO-NY72 cells. WT-NY72 and KO-NY72 cells maintained at 40°C were plated on
Oregon green 488-conjugated gelatin cross-linked glass coverslips and cultured at 37°C for 3 h. Cells were fixed and stained for actin and cortactin,
and cells degrading fluorescent gelatin were counted. (C) Invasion in Matrigel. WT-NY72 and KO-NY72 cells were applied to the upper well of
the Matrigel invasion chamber with or without serum in the lower well. After 24 h, Matrigel was removed and cells that passed through Matrigel
and penetrated the membrane were stained and their number determined. The numbers of invading cells are shown as means  SEM from three
independent assays. Typical photomicrographs are shown on the right.
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for v-Src targeting to the periphery as discussed above, and
that these actin fibers then undergo dissolution when targeted
v-Src exerts its action on transformation. Thus, the Rho para-
dox could be explained by a phase-dependent use of the Rho-
mediated actin cytoskeleton and its subsequent inhibition by a
feedback mechanism. A remaining question is whether the
above Rho-mediated mechanism is required only for initiation
of transformation or functions in a more subtle way in trans-
formed cells to maintain transformation. This should be clar-
ified by future studies.
FIG. 7. mDia1-deficient cells are impaired in tumorigenesis and invasion in vivo. (A) Tumor formation in nude mice. Nude mice underwent
subcutaneous injection of either WT-NY72 cells or KO-NY72 cells (3 105 per site) in the flank, three mice per group and two sites per mouse. Nineteen
days after inoculation, tumor formation at the injected sites was photographed. Inoculation of KO-NY72 cells developed no or very small tumors
compared to those from WT-NY72 cells (arrowheads). (B) Time course of tumor development. WT-NY72 and KO-NY72 cells were injected into nude
mice as described above, and the tumor volumes were measured as described in Materials and Methods. Each point represents a mean  SEM (n 

6). (C) Histological analysis. Tumors from WT-NY72 and KO-NY72 cells were taken at day 22 after inoculation, sectioned, and stained with hematoxylin
and eosin. Photomicrographs of a representative tumor from WT-NY72 cells and a sole tumor formed from six injections of KO-NY72 cells are shown.
Boxed areas are magnified below. Note that the tumor from WT-NY72 cells expands to both sides of the muscle layer (arrowheads). Bar, 5 mm.
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mDia1-mediated Src translocation is essential in oncogen-
esis. Here we have found that KO-NY72 cells that are defec-
tive in Src translocation are impaired in both in vitro transfor-
mation, such as colony formation in soft agar and focus
formation, and in vivo tumor formation in the xenograft trans-
plantation model, suggesting that mDia1-mediated transloca-
tion of v-Src first to focal adhesions and then to the cell mem-
brane is essential in oncogenic transformation. Src exhibits a
variety of discrete subcellular distribution, including plasma
membrane, adhesion plaques, cell-cell contact, and perinuclear
membranes (16, 19, 28, 29). Our findings are consistent with
the study by Hamaguchi and Hanafusa, who used various Src
mutants and found correlation between cytoskeletal associa-
tion and transforming activity (9), and the study by Liebl and
Martin, who prepared chimera molecules of v-Src and motifs
targeting to a specific subcellular site and found that v-Src
targeted to adhesion plaques can induce a transformation phe-
notype (19). Indeed, v-Src-induced tyrosine phosphorylation of
proteins was attenuated in KO-NY72 cells, particularly in pro-
teins of molecular masses above 100 kDa. By analyzing ty-
rosine phosphorylation of individual proteins and comparing
gene expression profiles of WT and KO cells, we have found
impaired tyrosine phosphorylation of proteins such as STAT3,
CAS, and p190 Rho GAP, as well as changes in gene expres-
sion in the KO cells (data not shown). We are in the process of
analyzing which events are crucial for v-Src-induced cell trans-
formation and tumorigenesis.
Rho-mDia1 functions as a link between oncogenesis and
invasion. Here we have found that KO-NY72 cells show im-
paired migration in the Matrigel invasion assay, suggesting that
mDia1 is required for invasion. Consistently, WT-NY72 cells
exhibited an invasive phenotype when transplanted into nude
mice. The current model of tumor invasion proposes two in-
terchangeable modes of movements: one is the proteolysis-
guided mesenchymal movement, and the other is the actomy-
osin-driven amoeboid movement (35). While the Rho-ROCK
pathway is critical in the latter, Rho signaling is also implicated
in the former. In the former process, matrix metalloproteases
(MMPs) are enriched in a specialized actin-rich structure
called podosomes and actively degrade ECM fibers to make a
path for tumor cells to invade. While the Cdc42–Arp2/3–N-
WASP pathway regulates actin filament assembly of podo-
somes (48), Rho signaling has also been indicated to be in-
volved in podosome induction. For example, Berdeaux et al.
(2) reported that an active GTP-bound form of Rho accumu-
lates in the podosome and that inactivation of Rho in v-Src-
transformed cells suppresses podosome formation and inhibits
Src-induced proteolytic degradation of ECM proteins. Nota-
bly, the podosome is resistant to treatment with Y-27632,
which led those authors to conceive that a Rho effector(s)
other than ROCK is involved in this process. Our results of
impaired podosome formation in KO-NY72 cells and colocal-
ization of mDia1 and Src in podosomes in wild-type cells sug-
gest that mDia1 is such an effector and that the mDia1-medi-
ated recruitment of Src to the membrane is linked to
podosome induction. In addition to what we have found here,
Kitzing et al. (17) found that mDia1 amplifies Rho-ROCK
activation in a positive feedback loop via a Rho GEF, LARG,
and also functions in amoeboid movement of MDA-MB-435
human cancer cells. These findings together have revealed that
the same molecule, mDia1, functions as a link between trans-
formation and invasion.
Clinical significance. Rho is overexpressed in many clinical
cancers (34), and its implication in human oncogenesis is
strongly suggested by a discovery that DlC-1, one of the Rho
GAPs, functions as a tumor suppressor in humans (47). Here
we have demonstrated a critical role of the Rho-mDia1 path-
way in v-Src-induced tumorigenesis. While v-Src itself is not a
cause of human cancers, activation of Src is implicated in many
human clinical cancers, including lung, skin, colon, breast,
ovarian, endometrial, and head and neck malignancies, sug-
gesting that c-Src facilitates oncogenesis by collaborating with
other signaling pathways (13). Our results indicate that Rho
signaling is one such pathway, functioning together with Src for
oncogenesis. The next question we have to address is whether
the Rho-mDia1 pathway has any role in oncogenesis induced
by oncogenes other than the v-Src gene, particularly that of
oncogenic Ras, because Ras-induced oncogenesis depends at
least in part on Rho signaling. Using mDia1-deficient mice for
skin oncogenesis and using MEF cells derived thereof for in
vitro transformation, we have found that mDia1 is essential in
Ras-mediated oncogenesis in vivo and in vitro (M. Tanji, T.
Ishizaki, and S. Narumiya, unpublished results). Whether the
mechanism we found in the present study operates in Ras-
mediated oncogenesis or whether another novel mechanism
operates there is a focus of our current study.
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